ECE2018 ePoster Presentations Pituitary and Neuroendocrinology (36 abstracts)
Acromegaly is chronic disease caused by hypersecretion of growth hormone (GH), most common caused by adenoma of pituitary gland. Cardiovascular risk, respiratory complication and malignancy are more common in this patients. Most often onset is between 30 to 50 years old, equally between gender. Therapy is almost always surgery, it can be combined with radiotherapy and gamma knife. Medicament therapy with somatostatin analogues, dopamine agonists and GH receptor antagonist. Goal is to show quality of life of patient that didnt underwent surgery treatment, with active acromegaly, aged 84 on analogs of somatostatin therapy for 12 years. Materials and methods: A case report. We used AcroQol questionnaire form on the start of disease and 10 years after.
Conclusion: Acromegaly is rare disease. In active form it is associated with significant morbidity and mortality. In our case during the follow up we diagnosed diabetes mellitus, hypertension, diastolic heart dysfunction stage I and cholecystectomy was preformed because of calculus (probably side effect of octreotide). Based on AcroQol questionnaire in 84 years old patients we conclude that in the beginning of the disease quality of life was reduced because of psychological characteristic/appearance (score −12, 5 vs −3, 4). Over the years condition is changing and physical characteristics were more dominant (score −3, 6 v.s. 0), which can be explained with patients age. Somatostatin analogs therapy in our case is efficient even after 12 years. Glycoregulation is good, and diastolic dysfunction is stable.
19 May 2018 - 22 May 2018